Imatinib mesylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Imatinib mesylate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
693
Registered trials
790
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Imatinib mesylate can convert its Small molecule drug profile and Bcr-Abl x PDGFRα x c-Kit biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Imatinib mesylate (query alias: Imatinib mesylate) |
|---|---|
| Modality / target | Small molecule drug; Bcr-Abl x PDGFRα x c-Kit; Bcr-Abl inhibitors, PDGFRα inhibitors, c-Kit inhibitors |
| Highest global status | Approved |
| Originator | Novartis Pharma AG |
| Active developers | Teva Pharmaceuticals Europe BV, Accord Healthcare SL, The Children's Oncology Group Foundation, Inc. |
The MCP disease footprint includes Accelerated phase Philadelphia chromosome positive chronic myeloid leukemia, Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07585266 | Phase 3 | Not yet recruiting | 800 | Progression-Free Survival (PFS) as assessed by Blinded independent central review (BICR) |
| NCT07530367 | Phase 3 | Not yet recruiting | 135 | Proportion of Participants Achieving PPPASI 90 Response at Week 16 |
| NCT07559370 | Phase 2 | Recruiting | 1116 | Dose of Imatinib (in mg) Required to Eliminate Viable Parasites |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Expanding access to tyrosine kinase inhibitors for treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia in low- and middle-income countries.
Not Applicable; n=1671; evaluation: Positive. Reported fields: AE = Since 2024, 25 patients received additional supportive services through The Max Foundation, including transportation assistance.
Cardiovascular toxicity of second-generation TKIs versus imatinib in first-line chronic myeloid leukemia: An updated systematic review and meta-analysis.
Not Applicable; n=1944; evaluation: Negative. Reported fields: all-cause mortality: RR = 1.28(95.0% CI, 0.85 - 1.92), P-Value = 0.24; all-cause mortality: RR = 1.28(95.0% CI, 0.85 - 1.92), P-Value = 0.24
Imatinib-related toxicity profile in patients with gastrointestinal stromal tumors seen over a twenty-year period in Ile-Ife, Nigeria.
Not Applicable; n=124; evaluation: Positive. Reported fields: Adverse Event: hypopigmentation = 35.6%
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Imatinib mesylate addresses Accelerated phase Philadelphia chromosome positive chronic myeloid leukemia, Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-07-06 | Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States | Preclinical | Financial terms not disclosed |
| 2021-03-29 | 国药控股与诺华肿瘤签署战略合作备忘录共同推进4款核心药品 | Approved | Financial terms not disclosed |
| 2021-02-09 | Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
